🔆 Beacon

← Search all trials on Beacon

A Study to Identify Breast Cancer (IDBC)

Recruiting now NCT04495244

Run by Syantra Inc. · for 30 to 75 · Women · accepts healthy volunteers

What this study is about

Detecting cancer as early as possible is key to achieving positive outcomes in response to diagnosis and treatment. The current project is aimed at validating a novel blood-based breast cancer identification test (Syantra DX Breast Cancer) that has been developed by Syantra Inc. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based upon test performance in a retrospective environment, a prospective validation study is being proposed. The primary objective of this study is to validate Syantra DX Breast Cancer methodology and biomarker panel using prospective samples, well categorized by diagnostic imaging scores, pathology outcomes, and subject characteristics.

Who can join (things the study team will check)

✅ You may be able to join if…

🚫 You may not be able to join if…

Where this trial is running

Who to contact

Natasha Jones · 0161 291 4045 · Natasha.Jones@mft.nhs.uk

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT04495244.

Open the interactive checklist for this trial →

Verify everything on the official ClinicalTrials.gov record. Page updated September 2026.

Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.